Bronze Sponsors: Smerud Medical Research, Eden Biodesign
Supporting Sponsors: TVM Capital, Scandinavian Life Science Venture, Coulter Partners, Imro Tramarko, Halsin Partners
Media Partners: New Scientist, Nature, Bio World, Pharmabiz
Summary of the Anglonordic Biotech Conference IV, 2007
On May 31, 2007, Ezenze, the Nordic Trade Councils, UK Trade & Investment and Atlas Venture organised the fourth Anglonordic Biotech Conference, which was held at the DTI’s Conference Centre in London.
The main aim of the conference was to promote and initiate partnerships, investment and alliances between the regions and provide information about the latest news on European biotech funding and strategic partnering. In total approximately 220 key decision makers from 180 biotechnology-, biopharmaceutical- and venture capital companies attended the one-day conference.
New to the conference 2007 was that is was divided up into four areas which had activities ongoing simultaneously. The four areas were the Main Conference Room, Atlas Venture’s Investment Room, the One-to-one meeting area and the Lounge & Exhibition area.
This year the conference had 104 pre-booked one-to-one meetings and assumable over 300 casual meetings were taking place in the lounge area.
A big success of the fourth conference was Atlas Venture’s Investment Room that offered 22 biotechnology companies the opportunity to do investment pitches in front of an audience of 45 European Investment firms and pharmaceuticals.
Conference Programme 2007
Chairman of the conference: Tim Sparey, Director, Scientific Liaison Licensing and External Research, Europe , Merck Sharp & Dohme
09.00 – 09.30 |
Registration and coffee |
|---|---|
| 09.30 – 09.40 | Introduction by the Chairman of the Conference |
| 09.40 – 09.50 | Welcome on behalf of Mr Staffan Carlsson, Ambassador of Sweden |
| 09.50 – 10.25 | Partnering Pitches |
| 10.25 – 10.50 | Collaboration Strategy at Merck to Facilitate Drug Discovery and Development - Examples from Early and Late Stage Deals and Acquisitions - Hans Boström, Director, Scientific Liaison, Licensing and External Research, Europe, Merck Sharp & Dohme |
10.50 – 12.10 |
The Next Thing in Drug Discovery |
| 12.10 – 13.10 | Lunch |
| 13.10 – 13.45 | Partnering Pitches - Galapagos - David Phillips, Senior Vice President - Lytix Biopharma - Øystein Rekdal, CEO - Cresset BioMolecular Discovery - Dr Sally Rose, Director |
| 13.45 – 14.15 | Top 10 tips from Bird & Bird on M&A and Corporate Transactions in the Life Science Sector - Matt Dennis, Partner, London & Sally Shorthose, Partner, London, Ulf Lundberg, Head of Life Science Sector Group, Stockholm, Bird & Bird |
| 14.15 – 14.45 | Early Phase Drug Development - Yvonne Lech, CEO, Capio Diagnostik and Knut T. Smerud, CEO, Smerud Medical Research International |
| 14.45 – 15.15 | Keeping Your Options Open: How European Biotechnology Companies Can Best Prepare for a Dual Exit Strategy – Dr Regina Hodits, Partner in the Life Science Sector, Atlas Venture LLP |
| 15.15 – 15.45 | Q&A and Conclusions |
| 15.45 – 19.00 | Buffet and Drinks |
Summary of the Anglonordic Biotech Conference III - 2006
On May 4, 2006, Ezenze, the Nordic Trade Councils and UK Trade & Investment organised the third Anglonordic Biotech Conference, which was held at the DTI’s Conference Centre in London.
The main aim of the conference was to promote and initiate partnerships and alliances between the regions and provide information about the latest news on European biotech funding and strategic partnering. In total approximately 170 key decision makers from 130 British and Nordic biotech, pharmaceutical and venture capital companies attended the one-day conference. 85% of the delegates were at CEO, CFO, VP or Investment Manager Level. Conference benefits included an interactive website with possibilities of pre-arranging meetings. On this years conference there were 91 pre-booked one-to-one meetings and assumable over 300 casual meetings. The evaluation made after the conference showed that 97% of the attending companies have had further business contacts with the companies visiting the conference. This conference was covered by several magazines such as "Nature", "New Scientist" etc
Gold sponsors   |
| Sponsors Awex (Wallonia Region of Belgium) Bavarian Nordic Capio Diagnostik Novo Nordisk Trigen |
Conference Programme 2006
Moderator: Mr Perry Yam, Partner, SJ Berwin LLP, Corporate Finance Department
| 09.30 - 10.00 | Registration and coffee |
| 10.00 - 10.10 | Conference Introduction Mr Perry Yam, Partner, SJ Berwin LLP |
| 10.10 10.20 |
Welcome on behalf of the Nordic Trade Councils and UK Trade & Investment - Mr Tom Risdahl Jensen, Ambassador of Denmark Dr Rob Morgan, Director, DTI Bioscience Unit |
| 10.20 - 11.40 | Elevator Pitches (4 company presentations) - Affitech, Martin Welschof, CEO - Bionor Immuno, Dr Birger Sørensen, CEO - ENKAM Pharmaceuticals, Morten Albrechtsen, CEO - Lyfjathroun hf, Thora Bjorg Magnusdottir, CEO |
| 11.40 - 12.10 |
(Case Study) Successful International Pharmaceutical agreements NicOx S.A's Ophthalmology Deal with Pfizer , presented by Damian Marron, Vice President Corporate Development, NicOx and Andrew Shindler, Partner, SJ Berwin LLP. Read the Case Study press release |
| 12.10 - 13.30 | Lunch |
| 13.30 - 14.00 | (Case Study) Successful M & A venture shares its experience from the M&A process Dr. Sanjay Kakkar, CEO, Trigen Ltd |
| 14.00 15.00 | Elevator Pitches (3 company presentations) - Neuronova, Johan Häggblad, Head of Business Development - NsGene, Bo Karmark, Chief Financial Officer - Tripep, Anders Vahlne, Head of Research |
| 15.00 15.30 | Latest news from the Venture Capital Industry (US versus Europe) Dr Nessan Bermingham, Principle of Life Sciences, Atlas Venture LLP |
| 15.30 - 16.00 | Q & A and panel discussions |
| 16.00 - 19.00 | Buffet and drinks |
Press here for a printable version of the schedule
Elevator Pitches
Affitech - "Creating a therapeutic antibody pipeline through technology-based collaborations and partnerships", Martin Welschof, CEO
Bionor Immuno - "HIV immunotherapy - presentation of clinicial phase II data." , Dr Birger Sørensen, CEO
ENKAM Pharmaceuticals - "generating novel treatments for neurodegenerative disorders and cancer, Morten Albrechtsen, CEO
Lyfjathroun hf - "Nasal drug delivery. Rapid systemic effect without the needle.", Þóra Björg Magnúsdóttir
Neuronova - "Therapeutic neurogenesis, new paradigm and treatment opportunity for neurology indications.", Johan Häggblad, Head Business Development
NsGene - "unique biodelivery technology to treat neurological disorders", Jens Viktor Nørgaard, Director of Intellectual Property Rights
Tripep - "New approaches for the treatment of HIV and hepatitis C virus infections", Anders Vahlne, Head of Research
Attending companies
3H Biomedical AB
3i
Abingworth
Activision Life International A/S
AcurePharma AB
AERES
Affitech AS
Alizyme
Amura
Antisoma
Atlas Venture
Avecia Ltd
Arrow Therapeutics Ltd
Astellas Pharma Europe
Awex
Axis-Shield plc
Bactus AB
Bavarian Nordic A/S
Bergen Techtrans Office AS
Bioanalab ltd
Biokapital Ltd
Biomedical Venture, BankInvest Group
Bionor Immuno
Biotec Pharmacon ASA
Biosergen AS
Birkeland Innovation AS
Cambridge Antibody Technology
Capio Diagnostik
CeNeS Pharmaceuticals plc
Center for Research on Pharmaceuticals
Chemilia
Curidium Limited
DiaGenic ASA
Domainex Ltd
DTI Global Watch Service
EiRx Therapeutics plc
ENKAM
Endocrine Pharmaceuticals Limited
Eurocine vaccines AB
Ezenze
Farallone Therapeutics BV
Forskningsstiftelsen
Giga
Glucox Biotech AB
Glycoform Ltd
HealthCap
Innovation Norwayz
Innovationskapital
Ionscope Ltd
Isis Innovation Ltd
ITX Corporation
Ixico Ltd
Kudos Pharmaceutical
Litis
London Stock Exchange
Ludesi
Lyfjathroun hf
Lytix Biopharma AS
Medinnova AS
MedPharm Ltd
MedTech Trondheim AS
Merck
Merlin Biosciences
MRC Technology (MRCT)
Nannovation Biotech Aps
NatImmune A/S
Naturejobs
NeuroNova
Nicox
Nova Thera Ltd
Novo Nordisk A/S
NsGene A/S
NTNU Technology Transfer AS
Olink Bioscience
Optinose AS
Orla Protein Technologies
Osteologix A/S
Oxford Immunotec Ltd
Oxigene, Inc
Paramount Biosciences
PharmaSurgics in Sweden AB
Pharmidex
PhotoCure ASA
Physiomics Plc
Phytopharma Plc
Pipeline Biotech A/S
Piramed
Proxima Concepts Ltd
Santosolve AS
Sareum Ltd
Sarsia Life Science Fund
Seymour Pierce Limited
Shire Pharmaceuticals Group Limited
SJ Berwin
SLP Innovations Ltd
Sophion Bioscience A/S
Stricent AB
Swedish Trade Council
SåkorninVest AS
The Embassy of Denmark in London
The Norwegian Radium Hospital Research Foundation
Therapeutic Antibody Centre
Thia Medica AS
Thiakis Ltd
TraceTag International Ltd
Trade Council of Denmark in the UK
Trade Council of Iceland
Trigen
Trillium Medical Ventures
Tripep AB
TTO Nord AS
UCB Celltech
UCL
UK Trade & Investment
Vipergen
Summary of the Anglo-Nordic Biotech Conference II - 2005
On April 21 2005, the Nordic Trade Councils and the London Stock Exchange organised a follow-up conference to the highly appreciated Anglonordic Biotech Conference I held 1 April 2004 at the DTI's Conference Centre in London. This conference was held at London Stock Exchanges selected premises in the centre of London.
The main aim of the conference was to promote and initiate partnerships and alliances between the regions and provide information about the latest news on European biotech funding and strategic partnering. In total approximately 150 key decision makers from 100 British and Nordic biotech, pharmaceutical and venture capital companies attended the one-day conference. Conference benefits included an interactive website with possibilities of pre-arranging meetings. In total approximately 50 partner meetings were carried out during the conference day.
Gold sponsors  |
| Sponsors Novo Nordisk Biofund Invest in Finland One NorthEast Scottish Development International UK Trade & Investment |
Conference Programme 2005
Attending companies
(Click on 3i to see an example of how each attending company will be presented on the website).
3i
4bio AS
Abingworth
Acasiatrade
ACE BioSciences
Action Pharma
Advent Ventures
Aeres Biomedical
Affitech
Algeta ASA
Alizyme Therapeutics
Amura
Antisoma Plc
Applied Photophysics
Arrow Therapeutics
Astellas Pharma
Atlas Venture
Attana AB
Auvation
Avecia
Bavarian Nordic
Beocarta
Bio World
BioCule
Biofocus Plc
Biofund
BioKapital
Bionor Immuno AS
BioVenture View
Business Wire
Cambridge Enterprise
Capman Life Science
Celltech Group Plc
CeNes Pharmaceutical
Cronos Therapeutics
Dagens Industri
Danish Trade Council
Dansk Erhvervsinvestering
D-Gen Ltd
Egalet Etna
Enkam Pharmaceuticals
ExpressOn
BioSystems Ltd
Ferring Pharmaceuticals
Finpro
Gastrotech Pharma
GlaxoSmithKline
Global Life Science Venture
Hannah InterActions Ltd
Haptogen
HealthCap
Icelandic Heart Association
Immunobiology
In vivo, Europe
Innovation Norway
Integrin Advanced Biosyst.
Invest in Finland
In Vivo
Invivo Communications
Ionix Pharmaceuticals
Isis Innovation
Juvantia Pharma Oy
Karocell Karyon Oy
Kauppalehti
Lipoxen
London Stock Exchange
Lorantis
Ludesi
LUX Biotech
Lyfjathroun hf
Medivir
Medpharm Ltd
Merck Sharp & Dohme
Merlin Biosciences
Nature New Business Venture Fund
Newham University Hospital NHS Trust
New Scientist
Nova Thera
Novel Diagnostics
Novo Nordisk
NsGene A/S
One NorthEast
Onyvax
Optinose
Orf Liftaekni ehf
Orla Protein Technologies
OstomyCure AS
Paul Capital Partners
Pfizer
PrediChem
Prokaria
Proteome Sciences
Plcf Santaris
Pharma Scancell Limited
Scottish Biomedical
Scottish Development Int
Shire Pharmaceutical
SJ Berwin
Skandinavian Life Science Venture
Swedish Trade Council
Swedish BioScience Prog
Såkorn Invest
Trade Council of Iceland
Tripep
UK Trade & Investment
Unicrop
University College London
Summary of the Anglo-Nordic Biotech Conference I - 2004
On April 1 2004, the Nordic Trade Councils together with the UK Trade & Investment organised the first follow-up conference to the highly appreciated Anglo-Swedish Biotech Conference II in April 2003 at
the London Stock Exchange in London. The Conference was held at DTI's selected Conference Centre on
1 Victoria Street.
In total approximately 160 key decision makers from 100 British and Nordic drug discovery, pharmaceutical and venture capital companies attended the one-day conference.
The main aim of the conference was to promote and initiate partnership and alliances between the regions, provide information about the latest news on European funding and to develop a forum that will make the
European biotech market even more competitive.
Conference benefits included an interactive website with possibilities of pre-arranging meetings.
Gold sponsor  |
| Silver Sponsors New Scientist UK Trade & Investment |
| Sponsors Novo Nordisk Biofund Embassy of Sweden Finn-Medi Research Iceland Air Invest in Finland I Invest in Sweden Agency Invest in Denmark Maersk Air |
Conference Programme 2004